gamma-Cyclodextrin hydrate | 91464-90-3

• 物质功能分类: 生物化工 - 糖类化合物 - 多糖
• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: gamma-Cyclodextrin hydrate
• 英文别名: (1S,3R,5R,6S,8R,10R,11S,13R,15R,16S,18R,20R,21S,23R,25R,26S,28R,30R,31S,33R,35R,36S,38R,40R,41R,42R,43R,44R,45R,46R,47R,48R,49R,50R,51R,52R,53R,54R,55R,56R)-5,10,15,20,25,30,35,40-octakis(hydroxymethyl)-2,4,7,9,12,14,17,19,22,24,27,29,32,34,37,39-hexadecaoxanonacyclo[36.2.2.23,6.28,11.213,16.218,21.223,26.228,31.233,36]hexapentacontane-41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56-hexadecol;hydrate
• CAS: 91464-90-3
• 化学式: C48H82O41
• 分子量: 1315.1
• InChiKey: SPKUKQHKKVTYOE-SMTXKKGASA-N

物化性质

• 熔点：
  267 °C (dec.)(lit.)
• 物理描述：
  DryPowder
• 稳定性/保质期：
  遵照规定使用和储存，则不会分解。

计算性质

• 辛醇/水分配系数(LogP)：
  -18.23
• 重原子数：
  89
• 可旋转键数：
  8
• 环数：
  30.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  634
• 氢给体数：
  25
• 氢受体数：
  41

安全信息

• TSCA：
  Yes
• 安全说明：
  S24/25
• WGK Germany：
  3
• 海关编码：
  35051000
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

文献信息

• NEW PHARMACEUTICAL COMPOSITIONS OF MELOXICAM WITH IMPROVED SOLUBILITY AND BIOAVAILABILITY
  申请人：Hexal AG

  公开号：EP1007049A1

  公开（公告）日：2000-06-14
• ASSOCIATIONS OF XANTHOGENATES AND CYCLODEXTRINS, AND THEIR USE
  申请人：Amtmann Eberhard

  公开号：US20100240606A1

  公开（公告）日：2010-09-23

  The invention is related to association products of xanthates and cyclodextrins, pharmaceutical formulations made therefrom, and medicaments containing these formulations for treating Alzheimer's, viral, tumor, cardiovascular, and autoimmune diseases such as rheumatism, multiple sclerosis, alopecia areata, lupus erythematosus, stroke, lung edema, or for use as radio-protectors. The association products contain a xanthate of general formula I whereby R 1 represents a possibly substituted aryl or alkyl residue and R 2 represents a metal atom, a possibly substituted alkyl, alkoxy, amino or ammonium group or halogen, and a cyclodextrin, whereby the cyclodextrin can be either a substituted or non-substituted alpha-, beta- or gamma-cyclodextrin. Furthermore, the invention is related to the use of the association products for chemical syntheses.
• US6284269B1
  申请人：——

  公开号：US6284269B1

  公开（公告）日：2001-09-04
• US8435966B2
  申请人：——

  公开号：US8435966B2

  公开（公告）日：2013-05-07
• [EN] NEW PHARMACEUTICAL COMPOSITIONS OF MELOXICAM WITH IMPROVED SOLUBILITY AND BIOAVAILABILITY<br/>[FR] NOUVELLES COMPOSITIONS PHARMACEUTIQUES DE MELOXICAM PRESENTANT UNE SOLUBILITE ET UNE BIODISPONIBILITE AMELIOREES
  申请人：HEXAL AG

  公开号：WO1999009988A1

  公开（公告）日：1999-03-04

  (EN) Pharmaceutical compositions containing enolic carboxamide type antiinflammatory agent meloxicam that exhibit improved wettability, aqueous solubility, dissolution behaviour over a broad range of pH, and that are prepared by crystal structure modification of the drug through dry or wet mechanical homogenization with two further components - one of them is selected from a group of oligo - and dissolution improving, or alkalizing agent. The application of the formulations according to the present invention results in an improved biovailability and effectiveness of meloxicam.(FR) Compositions pharmaceutiques contenant un agent anti-inflammatoire de type carboxamide énolique, désigné meloxicam, présentant des caractéristiques améliorées de mouillabilité, de solubilité aqueuse, de comportement à la dissolution sur une plage importante de pH et dont la préparation consiste à modifier la structure cristalline du médicament par homogénéisation mécanique sèche ou humide avec deux constituants supplémentaires, dont l'un est sélectionné dans un groupe oligo améliorant la dissolution ou consiste en un agent d'alcalinisation. Ces formulations permettent d'améliorer la biodisponibilité et l'efficacité de meloxicam.